by Mark Curtis | Dec 4, 2014
. The Edmonton Protocol for the transplantation of insulin producing cells into individuals with type 1 diabetes (T1DM) has a cost per quality-adjusted life year (QALY) of ~$165,000. This is more than three times the willingness-to-pay (WTP) in Canada, and comfortably...
by Mark Curtis | Nov 20, 2014
. You have all by now heard that Dendreon has filed for bankruptcy protection. If you’re a regular reader of Signals, you may have first heard the news here. While the company has successfully reached agreements on a financial restructuring with a majority of its...
by Sara M. Nolte | Sep 29, 2014
> It’s September again! That means new grad students in the lab, seminars and courses start again, committee meetings, grant deadlines, product shows, and… Journal Club. What is Journal Club – and why am I about to spend an entire post talking about it? Ideally, it...
by David Brindley | Sep 23, 2014
. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute. Assume a single bacterium weighs one thousand billionth of a gram. If it, and each of its...
by Mark Curtis | Sep 18, 2014
. Welcome to your Update from the Clinic for the month of August. Asterias Biotherapeutics breathes new life into a cell therapy shelved two years ago and initiates a Phase I/II study in patients with spinal cord injury. Northwest Biotherapeutics provides an update on...
Comments